$CLXT News
Last published 1y ago
- 1y agoCBUSCLLSMGXCLXTTotus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial OfficerGlobeNewswireEMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the
- 3y agoCLXTCalyxt Announces Stockholder Approval of Merger With CibusPR Newswire-- Calyxt Announces 1-for-5 Reverse Stock Split of Common Stock -- ROSEVILLE, Minn., May 19, 2023 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT) ("Calyxt" or the "Company") today announced the results of the
- 3y agoCLXTCalyxt Reports First Quarter 2023 Financial Results and Provides Corporate UpdatePR Newswire—Proposed merger with Cibus Global Expected to Close in Q2 2023— —1-for-10 reverse stock split executed— —Current customer projects under development are on track— —Evologic Technologies completed initial phase of
- 3y agoCLXTCalyxt Completes One-for-Ten Reverse Stock SplitPR NewswireROSEVILLE, Minn., April 24, 2023 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT) ("Calyxt" or the "Company") today announced that it has completed the previously announced reverse stock split of Calyxt's
- 3y agoCLXTCalyxt, Inc. Announces Effectiveness of Registration Statement on Form S-4 in Connection with Merger with Cibus Global LLCPR NewswireROSEVILLE, Minn. and SAN DIEGO, April 18, 2023 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, today announced that the
- 3y agoCLXTCalyxt Announces Effective Date of Reverse Stock SplitPR NewswireROSEVILLE, Minn., April 7, 2023 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT) ("Calyxt" or the "Company") today announced that it will proceed with the 1-for-10 reverse stock split previously approved by the
- 3y agoCLLSCLXTCalyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswireNEW YORK, March 06, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced
- 3y agoCLXTCalyxt Reports Fourth Quarter 2022 Financial Results and Provides Corporate UpdatePR Newswire—Announced proposed merger with Cibus Global and filed initial registration statement on Form S-4— —Current customer projects under development are on track— —Signed agreement with Evologic Technologies to further
- 3y agoCLXTCalyxt, Inc. Announces its Filing of Registration Statement on Form S-4 in Connection with Merger with Cibus Global LLCPR NewswireROSEVILLE, Minn. and SAN DIEGO, Feb. 15, 2023 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, today announced that Calyxt
- 3y agoCLLSCLXTCalyxt and Cibus Announce the Signing of a Definitive Merger AgreementGlobeNewswireNEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Cellectis (NASDAQ:CLLS), a clinical-stage biotechnology company using its gene editing platform to deliver life-saving cell and gene therapies, announced today that Cibus
- 3y agoBIOXCLXTCalyxt and Cibus Announce Definitive Merger Agreement to Create Industry-Leading Precision Gene Editing and Trait Licensing CompanyPR Newswire– The merger will bring together the technology platforms and facilities of two pioneering companies to create a leader in precision gene editing focused on driving sustainable agriculture and the availability of
- 3y agoCLXTCalyxt Achieves Phase 1 Milestone in Collaboration Agreement to Develop Alternative to Palm OilPR NewswireROSEVILLE, Minn., Nov. 18, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biology company announced today that it has successfully completed the first phase in its research collaboration
- 3y agoCLXTCalyxt Granted 180-Day Extension by Nasdaq to Regain Compliance with Bid Price RulePR NewswireROSEVILLE, Minn., Nov. 17, 2022 /PRNewswire/ -- Calyxt, Inc (NASDAQ:CLXT) a plant-based synthetic biology focused on engineering sustainable ingredients for customers in the cosmeceutical, nutraceutical and
- 4y agoCLXTCalyxt Reports Third Quarter 2022 Financial Results and Provides Corporate UpdatePR Newswire—Successfully produced squalene, an important ingredient for personal care products and vaccine adjuvants— —Continued to progress customer acquisition activities, including evaluating an incremental 37 customer
- 4y agoCLXTCalyxt Joins Bioindustrial Manufacturing and Design Ecosystem (BioMADE), a Department of Defense Initiative, to Advance Sustainable Plant-Based BiomanufacturingPR Newswire-Calyxt joins a select network of synthetic biology companies, top-tier academic institutions, research-focused not-for-profits, and US government agencies dedicated to innovating and growing the bioeconomy- ROSEVILLE,
- 4y agoCLXTCalyxt to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Thursday, November 3, 2022, at 4:30 p.m. Eastern TimePR NewswireROSEVILLE, Minn., Oct. 27, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biology company, will host a conference call and webcast on Thursday, November 3, 2022, at 4:30 p.m. ET to discuss
- 4y agoCLXTCalyxt Successfully Produces Plant-Based Squalene, an Important Ingredient in Personal Care Products and Critical Vaccine AdjuvantsPR NewswireROSEVILLE, Minn., Oct. 25, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biology company, announced today that using a Calyxt-engineered Plant Cell Matrix™ biomass, it has successfully
- 4y agoCLXTCalyxt Announces Agreement with Evologic Technologies to Scale Production of its Plant-based IngredientsPR NewswireAgreement will power speed-to-scale strategy to meet the growing interest in high-quality sustainable ingredients across the cosmeceutical, nutraceutical and pharmaceutical markets ROSEVILLE, Minn., Oct. 6, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLX
- 4y agoCLXTCalyxt, Inc. Exploring Strategic AlternativesPR NewswireROSEVILLE, Minn., Sept. 22, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT) ("Calyxt"), a plant-based synthetic biology company, today announced that its Board of Directors is evaluating potential strategic alternatives to maximize shareholder value. As
- 4y agoCLXTCalyxt to Present at the H.C. Wainwright 24th Annual Global Investment ConferencePR NewswireROSEVILLE, Minn., Sept. 7, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biology company, today announced that Michael A. Carr, President and Chief Executive Officer, and Bill Koschak, Chief Financial Officer, will present at
- 4y agoCLXTCalyxt Reports Second Quarter 2022 Financial Results and Provides Corporate UpdatePR NewswireEvaluated nine new customer demand-driven plant-based chemistries in the quarter, bringing cumulative chemistries evaluated for development to 95, of these 31 meet Calyxt's target profile and several are the subject of term sheet discussions Engineerin
- 4y agoCLXTCalyxt to Present at the Canaccord Genuity 42nd Annual Growth ConferencePR NewswireROSEVILLE, Minn., July 28, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biology company, today announced that Michael A. Carr, Chief Executive Officer, and Bill Koschak, Chief Financial Officer, will present at the Canaccord
- 4y agoCLXTCalyxt to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Thursday, August 4, 2022, at 4:30 p.m. Eastern TimePR NewswireROSEVILLE, Minn., July 21, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biology company, will host a conference call and webcast on Thursday, August 4, 2022, at 4:30 p.m. Eastern Time to discuss results for the second quar
- 4y agoCLXTCalyxt to Present at Upcoming ConferencesPR NewswireROSEVILLE, Minn., May 17, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biology company, today announced that management will participate in the following upcoming investor conferences:
- 4y agoCLLSCLXTCalyxt, Inc., Cellectis' Majority-Owned Subsidiary, Reports Its First Quarter 2022 Financial ResultsGlobeNewswireNEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that Calyxt, Inc. (NASDAQ:CLXT),
- 4y agoCLXTCalyxt Reports First Quarter 2022 Financial ResultsPR NewswireAchieved technical BioFactory™ and AIML milestones to support customer demand-driven molecule development at scale Progressed relationships with an expanding network of potential new customers across the cosmeceutical and flavor and fragrance end mar
- 4y agoCLXTCalyxt Announces Strategic Hires in Business Development and ManufacturingPR NewswireContinued investment in key hires to strategically position Company for future growth and scale ROSEVILLE, Minn., April 26, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biotechnology company, yesterday welcomed the second
- 4y agoCLXTCalyxt to Host First Quarter 2022 Financial Results Conference Call and Webcast on Thursday, May 5, 2022, at 4:30 p.m. Eastern TimePR NewswireROSEVILLE, Minn., April 21, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biology company, will host a conference call and webcast on Thursday, May 5, 2022, at 4:30 p.m. Eastern Time to discuss results for the first quarter en
- 4y agoCLXTCalyxt to Participate in Fireside Chat at the 34th Annual Roth ConferencePR NewswireROSEVILLE, Minn., March 8, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biology company, today announced that management will participate in a fireside chat at the 34th Annual Roth Conference at the Ritz-Carlton in Dana Poin
- 4y agoCLXTCalyxt Reports Fourth Quarter and Full Year 2021 Financial ResultsPR NewswireROSEVILLE, Minn., March 3, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biology company, today announced financial results for its fourth quarter and full year ended December 31, 2021.
- 4y agoCLXTCalyxt to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call on Thursday, March 3, 2022, at 4:30 p.m. Eastern TimePR NewswireROSEVILLE, Minn., Feb. 24, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biology company, will hold a conference call on Thursday, March 3, 2022, at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter and ful
- 4y agoCLXTCalyxt Announces Closing of SEC-Registered Offering of Common Stock, Pre-Funded Warrants to Purchase Common Stock and Warrants to Purchase Common StockPR NewswireROSEVILLE, Minn., Feb. 23, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT) ("Calyxt" or the "Company"), a plant-based synthetic biology company, today announced the closing of its previously announced placement to an institutional investor in an underwr
- 4y agoCLLSCLXTCalyxt Announces Pricing of Offering Of Common Stock and Warrants and Updates Business and Risk Factor DisclosureGlobeNewswireNEW YORK, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Cellectis (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, and Calyxt, Inc. ("Calyxt"), a majority-owned (61.8%
- 4y agoCLXTCalxyt, Inc. Announces Pricing of $10.9 Million SEC-Registered Offering of Common Stock and WarrantsPR NewswireROSEVILLE, Minn., Feb. 17, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT) ("Calyxt" or the "Company"), a plant-based synthetic biology company, today announced the placement to an institutional investor in an underwritten offering of 3,880,000 shares of
- 4y agoCLXTCalyxt Announces Gerry Nuovo as Senior Vice President of Business DevelopmentPR NewswireROSEVILLE, Minn., Feb. 7, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biotechnology company, today announced that Gerry Nuovo has joined Calyxt as Senior Vice President of Business Development. He brings more than 30 years
- 4y agoCLXTCalyxt Announces Pilot BioFactory™ Production System Now OperationalPR NewswireROSEVILLE, Minn., Jan. 6, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biotechnology company, today announced that its pilot BioFactory™ production system, installed in late December 2021, is now operational at its headqua
- 4y agoCLXTCalyxt to Present at the H.C. Wainwright BioConnect Virtual ConferencePR NewswireROSEVILLE, Minn., Jan. 4, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biotechnology company today announced that a presentation given by management at the H.C Wainwright BioConnect Conference will be available for viewing onl
- 4y agoCLXTCalyxt Identifies More Than 15,000 Unique Chemical Signatures in Lab-Scale BioFactory™ Production RunPR NewswireROSEVILLE, Minn., Dec. 8, 2021 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biotechnology company, today announced the completion of a key milestone in its lab-scale BioFactory™ manufacturing system. The results identified throu
- 4y agoCLXTCalyxt Announces Strategic Hires in AI/ML and Technology LicensingPR NewswireROSEVILLE, Minn., Dec. 6, 2021 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biotechnology company, today announced the hiring of two senior roles important to furthering Calyxt's recently announced strategic direction. Joining t
- 4y agoCLXTCalyxt to Present at the 2021 Canaccord Genuity AgriFood Tech Innovation Virtual ForumPR NewswireROSEVILLE, Minn., Nov. 23, 2021 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biotechnology company, today announced that management will present at the 2021 Canaccord Genuity AgriFood Tech Innovation Virtual Forum. 2021 Canacco
- 5y agoCLXTCalyxt Reports Third Quarter 2021 Financial ResultsPR NewswireROSEVILLE, Minn., Nov. 4, 2021 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biotechnology company, today announced financial results for its third quarter ended September 30, 2021. "Since I joined the Company as CEO in July, Ca
- 5y agoCLXTCalyxt to Host third Quarter 2021 Financial Results Conference Call on Thursday, November 4, 2021, at 4:30 p.m. Eastern TimePR NewswireROSEVILLE, Minn., Oct. 19, 2021 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT) will hold a conference call on Thursday, November 4, 2021, at 4:30 p.m. Eastern time to discuss its results for the third quarter ended on September 30, 2021. A press release de
- 5y agoCLXTCalyxt Names IBM's Global Chief Artificial Intelligence Officer, Dr. Seth Dobrin, to Scientific Advisory BoardPR NewswireROSEVILLE, Minn., Oct. 12, 2021 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biotechnology company, today announced the appointment of Seth Dobrin, Ph.D., to the Company's Scientific Advisory Board (SAB). Dr. Dobrin is the Globa
- 5y agoCLXTCalyxt Announces Collaboration with Leading Global Food Ingredient Manufacturer to Develop Palm Oil AlternativePR NewswireROSEVILLE, Minn., Sept. 28, 2021 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based technology platform company, today announced it entered into a research collaboration with a leading global food ingredient manufacturer based in Asia to develo
- 5y agoCLXTCalyxt to Present at the H.C Wainwright 23rd Annual Global Investment ConferencePR NewswireROSEVILLE, Minn., Sept. 7, 2021 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based technology platform company, today announced that a presentation given by management at the H.C Wainwright 23rd Annual Global Investment Conference will be availab
- 5y agoCLXTCalyxt to Present at the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021PR NewswireROSEVILLE, Minn., Aug. 4, 2021 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based biotechnology platform company, today announced that management will present at the Canaccord Genuity 41st Annual Growth Conference at 11:00 a.m. ET. The conferenc
- 5y agoCLXTCalyxt Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)PR NewswireROSEVILLE, Minn., July 27, 2021 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based biotechnology platform company, today announced that, in accordance with the offer letter entered into on July 15, 2021, it has granted, effective July 27, 2021 (t
- 5y agoCLXTCalyxt to Host Second Quarter 2021 Financial Results Conference Call on Thursday, August 5, 2021 at 4:30 p.m. Eastern TimePR NewswireROSEVILLE, Minn., July 19, 2021 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT) will hold a conference call on Thursday, August 5, 2021 at 4:30 p.m. Eastern time to discuss its results for the second quarter ended on June 30, 2021. A press release detailing
- 5y agoCLXTCalyxt Appoints Michael A. Carr as Chief Executive OfficerPR NewswireROSEVILLE, Minn., July 15, 2021 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based biotechnology platform company, today announced the appointment of Michael A. Carr as President and Chief Executive Officer, effective July 27, 2021. Mr. Carr will
- 5y agoCLXTCalyxt Announces Expansion of Hemp Breeding Platform with Seedless Hemp InnovationACCESS NewswireTriploid Breeding Process is Calyxt's Second Announced Advancement and Part of a Comprehensive Approach to Improving Hemp Genetics ROSEVILLE, MN / ACCESSWIRE / July 8, 2021 / Calyxt, Inc. (NASDAQ:CLXT), today announced further expansion of its hemp bree